Privacy Policy
Signals Blog

Contributors

Categories

Cell Therapy Commercialization: Look for Headroom

. Of all the formidable challenges that a biotechnology company will stumble upon in its quest to commercialize, perhaps there is none more frustrating than a failure to get a product reimbursed by payers. After years of navigating the gauntlet of risk that is...

Right Turn: Time to stop the bleeding

Recently Revmedx, a pioneer in the biomaterial wound dressing field, made some waves with the commercialization of its product XStatTM . XStatTM received a lot of press because of its FDA approval for use against gunshot wounds and shrapnel-related injuries in the...

Right Turn: Bringing stem cells to (fictional) life

> I’ve been thinking a fair bit about the “personalities” of stem cells in recent weeks — specifically, the characteristics of stem cells that might translate into a persona or a fictional character of some sort. It’s with good reason,...

Cell lines, patient samples, and cultures – oh my!

> The thing that is so intriguing about cancer stem cells (CSCs), from a cancer researcher’s perspective, is their powerful potential as therapeutic targets. While CSCs can create or regenerate tumours (causing relapse in some patients despite our best efforts to...

Right Turn: Autism, Stem Cells and the Tooth Fairy

. This intriguing title is not completely my own. It is a shorter version of Alysson Muotri’s  (UCSD) title from a presentation he gave to the governing Board of the California Institute of Regenerative Medicine on March 13, 2014: “Reversing Autism in the Lab with...

Right Turn: Stripping down to the muscle

> Michael Rudnicki has been studying muscle biology for a long time… all the way back to his days as a graduate student. In this time, he’s contributed greatly to our understanding about muscle formation and the molecular “switches” that...

Subscribe to Signals

Subscribe to our blog list to receive the latest news and updates.

You have Successfully Subscribed!